Article
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
The Lancet. Oncology - 1 Sept 2015
Pastore Alessandro, Jurinovic Vindi, Kridel Robert, Hoster Eva, Staiger Annette M, Szczepanowski Monika, Pott Christiane, Kopp Nadja, Murakami Mark, Horn Heike, Leich Ellen, Moccia Alden A, Mottok Anja, Sunkavalli Ashwini, Van Hummelen Paul, Ducar Matthew, Ennishi Daisuke, Shulha Hennady P, Hother Christoffer, Connors Joseph M, Sehn Laurie H, Dreyling Martin, Neuberg Donna, Möller Peter, Feller Alfred C, Hansmann Martin L, Stein Harald, Rosenwald Andreas, Ott German, Klapper Wolfram, Unterhalt Michael, Hiddemann Wolfgang, Gascoyne Randy D, Weinstock David M, Weigert Oliver
Abstract excerpt
BACKGROUND: Follicular lymphoma is a clinically and genetically heterogeneous disease, but the prognostic value of somatic mutations has not been systematically assessed. We aimed to improve risk stratification of patients receiving first-line immunochemotherapy by integrating gene mutations into a prognostic model. METHODS: We did DNA deep sequencing to retrospectively analyse the mutation status of 74 genes in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.